A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Marizomib (Primary) ; Temozolomide
Indications Glioblastoma
Focus Registrational; Therapeutic Use
Acronyms MIRAGE

Most Recent Events

05 Sep 2024 Results published in the Neuro-Oncology.
25 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
23 May 2023 Planned End Date changed from 1 Jul 2023 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight